Wikipedia -WSS

Wikipedia

author：entertainment 2025-10-02 21:05:36 - browse：124

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Friends ask where James Watson's attitudes about race came from

WSS

There’s a way to spot data fakery. All journals should be using it

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

The best solution to the drug shortages problem

Why failed clinical trials don’t always spell doom for a new drug

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

There’s a way to spot data fakery. All journals should be using it

Affirmative action in medical school literally saved lives

South Korea throws huge K

The high cost of giving birth even with insurance

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Peter Hotez and the public health issue of online harassment

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Sports medicine is finally prioritizing gender equality

Drastic changes should bring profitability, startup health insurers say

hotspot

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

'CMA Fest' 2023: How to watch, who is performing and more

Man killed during FBI raid in connection with threats against Biden, other officials

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Drastic changes should bring profitability, startup health insurers say

knowledge

hotspot

explore

entertainment